3SBio Inc - Asset Resilience Ratio

Latest as of December 2025: 10.64%

3SBio Inc (83B) has an Asset Resilience Ratio of 10.64% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€3.86 Billion

≈ $4.51 Billion USD Cash + Short-term Investments

Total Assets

€36.25 Billion

≈ $42.38 Billion USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how 3SBio Inc's Asset Resilience Ratio has changed over time. Check 3SBio Inc (83B) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down 3SBio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 83B market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€3.86 Billion	10.64%
Total Liquid Assets	€3.86 Billion	10.64%

Asset Resilience Insights

Moderate Liquidity: 3SBio Inc has 10.64% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

3SBio Inc Industry Peers by Asset Resilience Ratio

Compare 3SBio Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	10.93%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
SOLENO THERAPEUT. DL-001 F:6XC	Biotechnology	41.74%
Galapagos NV F:GXEA	Biotechnology	86.45%
Nanobiotix S.A PA:NANO	Biotechnology	53.40%
Chengdu Easton Biopharmaceuticals Co Ltd SHG:688513	Biotechnology	34.30%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for 3SBio Inc (2016–2025)

The table below shows the annual Asset Resilience Ratio data for 3SBio Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	10.64%	€3.86 Billion ≈ $4.51 Billion	€36.25 Billion ≈ $42.38 Billion	-4.93pp
2024-12-31	15.57%	€3.77 Billion ≈ $4.41 Billion	€24.21 Billion ≈ $28.31 Billion	+1.59pp
2023-12-31	13.98%	€3.30 Billion ≈ $3.86 Billion	€23.63 Billion ≈ $27.62 Billion	-8.13pp
2022-12-31	22.11%	€4.86 Billion ≈ $5.68 Billion	€21.99 Billion ≈ $25.71 Billion	+12.22pp
2021-12-31	9.89%	€1.90 Billion ≈ $2.22 Billion	€19.21 Billion ≈ $22.46 Billion	+2.69pp
2020-12-31	7.20%	€1.27 Billion ≈ $1.49 Billion	€17.68 Billion ≈ $20.67 Billion	+4.01pp
2019-12-31	3.19%	€472.16 Million ≈ $552.01 Million	€14.81 Billion ≈ $17.31 Billion	+2.70pp
2018-12-31	0.49%	€68.13 Million ≈ $79.65 Million	€13.84 Billion ≈ $16.18 Billion	-4.63pp
2017-12-31	5.12%	€704.56 Million ≈ $823.71 Million	€13.75 Billion ≈ $16.08 Billion	+1.84pp
2016-12-31	3.28%	€362.17 Million ≈ $423.42 Million	€11.04 Billion ≈ $12.91 Billion	--

pp = percentage points

About 3SBio Inc

F:83B Germany Biotechnology

Market Cap

$5.59 Billion

€4.78 Billion EUR

Market Cap Rank

#3337 Global

#627 in Germany

Share Price

€1.91

Change (1 day)

+3.33%

52-Week Range

€1.63 - €3.88

All Time High

€3.88